TY - JOUR
T1 - Distribution of crushing strength of tablets
AU - Sonnergaard, Jørn
PY - 2002/1/1
Y1 - 2002/1/1
N2 - The distribution of a given set of data is important since most parametric statistical tests are based on the assumption that the studied data are normal distributed. In analysis of fracture mechanics the Weibull distribution is widely used and the derived Weibull modulus is interpreted as a material constant. However, the estimation of this parameter is laborious and subject to estimation problems. It is shown that the Weibull modulus is inherently connected to the coefficient of variation and that the information obtained from the modulus is unclear. The distribution of crushing strength data from nine model tablet formulations and four commercial tablets are shown to follow the normal distribution. The importance of proper cleaning of the crushing strength apparatus is demonstrated.
AB - The distribution of a given set of data is important since most parametric statistical tests are based on the assumption that the studied data are normal distributed. In analysis of fracture mechanics the Weibull distribution is widely used and the derived Weibull modulus is interpreted as a material constant. However, the estimation of this parameter is laborious and subject to estimation problems. It is shown that the Weibull modulus is inherently connected to the coefficient of variation and that the information obtained from the modulus is unclear. The distribution of crushing strength data from nine model tablet formulations and four commercial tablets are shown to follow the normal distribution. The importance of proper cleaning of the crushing strength apparatus is demonstrated.
UR - http://www.scopus.com/inward/record.url?scp=0036213360&partnerID=8YFLogxK
U2 - 10.1016/S0939-6411(02)00014-0
DO - 10.1016/S0939-6411(02)00014-0
M3 - Journal article
AN - SCOPUS:0036213360
SN - 0939-6411
VL - 53
SP - 353
EP - 359
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
IS - 3
ER -